PMID- 37116152
OWN - NLM
STAT- MEDLINE
DCOM- 20230503
LR  - 20230720
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 24
IP  - 4
DP  - 2023 Apr 1
TI  - Anti-tumor Effects of IL-1beta Induced TRAIL-Expressing hUCMSCs on Embelin Treated 
      Breast Cancer Cell Lines.
PG  - 1297-1305
LID - 90604 [pii]
LID - 10.31557/APJCP.2023.24.4.1297 [doi]
AB  - BACKGROUND: Human umbilical cord mesenchymal stem cells (hUCMSCs) have high 
      therapeutic value in cancer treatment. We have found that pre-activating hUCMSCs 
      with IL-1beta promotes tumor necrosis factor-related apoptosis inducing ligand 
      (TRAIL) expression and facilitates anti-tumor effect. Furthermore, embelin has 
      been found to induce apoptosis of different cancer cell lines by upregulating the 
      expression of TRAIL receptor 1 (DR4) and TRAIL receptor 2 (DR5). This study 
      investigated whether IL-1beta induced TRAIL-expressing hUCMSCs, in combination with 
      low-dose embelin, could further induce apoptosis in breast cancer cell lines. 
      MATERIALS AND METHODS: MTT assay was used to examine the cytotoxicity of embelin 
      in MDA-MB-231 and MCF-7. To detect the interested protein expression in cells, 
      Western blot and cell immunofluorescence were used to double-confirm the observed 
      results. Annexin V/PI apoptosis assay was detected by flow cytometry to analyze 
      the apoptosis rate of embelin treated breast cancer cell lines and the effect of 
      co-culturing with breast cancer cells and hUCMSCs. RESULTS: Using Western blot 
      and immunofluorescence, we found that breast cancer cell lines treated with 
      low-dose embelin (2.5-5 muM) increased the expression of apoptosis-related 
      receptor DR4, DR5 and the cleaved caspase 8, 9 and 3. Moreover, TRAIL expression 
      was enhanced in IL-1beta induced hUCMSCs. Combining these observations, we expected 
      that coculturing IL-1beta induced hUCMSCs with low dose embelin treated MDA-MB-231 
      and MCF-7 cells might enhance the apoptosis of breast cancer cells. We confirmed 
      via flow cytometry that coculture of IL-1beta induced TRAIL-expressing hUCMSCs and 
      embelin treated MDA-MB-231 and MCF-7 cells enhances the apoptosis rate of these 
      breast cancer cells. CONCLUSION: We found that embelin upregulated the expression 
      of DR4 and DR5 to increase the TRAIL-mediated apoptosis in breast cancer cell 
      lines. Low dose embelin treated breast cancer cell lines in combination with 
      IL-1beta induced TRAIL-expressing hUCMSCs may become a potential anti-tumor therapy.
FAU - Teng, Jui-Wen
AU  - Teng JW
AD  - Institute of Anatomy and Cell Biology, School of Medicine, National Yang Ming 
      University, Taipei, Taiwan, ROC.
FAU - Hung, Eric
AU  - Hung E
AD  - Institute of Anatomy and Cell Biology, School of Medicine, National Yang Ming 
      University, Taipei, Taiwan, ROC.
FAU - Wu, Jiann-Ming
AU  - Wu JM
AD  - General Surgery Division, Far Eastern Memorial Hospital, New Taipei City, Taiwan, 
      ROC.
FAU - Liang, Ya-Han
AU  - Liang YH
AD  - Institute of Anatomy and Cell Biology, School of Medicine, National Yang Ming 
      University, Taipei, Taiwan, ROC.
FAU - Chiu, Yun-Hsuan
AU  - Chiu YH
AD  - Institute of Anatomy and Cell Biology, School of Medicine, National Yang Ming 
      University, Taipei, Taiwan, ROC.
FAU - Tyan, Yeu-Sheng
AU  - Tyan YS
AD  - Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, 
      Taiwan, ROC.
FAU - Wang, Hwai-Shi
AU  - Wang HS
AUID- ORCID: 0000-0003-1818-0970
AD  - Institute of Anatomy and Cell Biology, School of Medicine, National Yang Ming 
      University, Taipei, Taiwan, ROC.
LA  - eng
PT  - Journal Article
DEP - 20230401
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - SHC6U8F5ER (embelin)
RN  - 0 (Ligands)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Interleukin-1beta)
SB  - IM
MH  - Female
MH  - Humans
MH  - Apoptosis
MH  - *Breast Neoplasms/drug therapy
MH  - Cell Line, Tumor
MH  - Ligands
MH  - MCF-7 Cells
MH  - *Mesenchymal Stem Cells/metabolism
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism
MH  - TNF-Related Apoptosis-Inducing Ligand/pharmacology
MH  - Tumor Necrosis Factor-alpha
MH  - Interleukin-1beta/pharmacology
PMC - PMC10352746
OTO - NOTNLM
OT  - Human umbilical cord mesenchymal stem cells (hUCMSCs)
OT  - anti-tumor therapy
OT  - breast cancer cell
OT  - tumor necrosis factor-related apoptosis inducing ligand (TRAIL)
COIS- The authors declare no conflicts of interest.
EDAT- 2023/04/28 18:42
MHDA- 2023/05/01 06:42
PMCR- 2023/03/01
CRDT- 2023/04/28 16:07
PHST- 2022/12/06 00:00 [received]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 18:42 [pubmed]
PHST- 2023/04/28 16:07 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 90604 [pii]
AID - 10.31557/APJCP.2023.24.4.1297 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1297-1305. doi: 
      10.31557/APJCP.2023.24.4.1297.